Millennium Management’s Karyopharm Therapeutics KPTI Stock Holding History

Millennium Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$507K	Buy	+91,000	New	+$694K	﹤0.01%	4761
2023 Q4	–	Sell	-8,667	Closed	-$174K	–	6319
2023 Q3	$174K	Buy	+8,667	New	+$195K	﹤0.01%	5174
2022 Q3	–	Sell	-6,667	Closed	-$451K	–	7297
2022 Q2	$451K	Buy	+6,667	New	+$612K	﹤0.01%	5045
2021 Q1	–	Sell	-19,913	Closed	-$4.62M	–	6252
2020 Q4	$4.62M	Buy	+19,913	New	+$4.61M	﹤0.01%	2522
2020 Q3	–	Sell	-13,333	Closed	-$3.79M	–	4652
2020 Q2	$3.79M	Buy	13,333 +10,000	+300%	+$2.96M	0.01%	2014
2020 Q1	$961K	Buy	+3,333	New	+$919K	﹤0.01%	2493
2019 Q3	–	Sell	-33,333	Closed	-$3M	–	4375
2019 Q2	$3M	Buy	+33,333	New	+$2.68M	﹤0.01%	2148
2018 Q2	–	Sell	-2,740	Closed	-$552K	–	3984
2018 Q1	$552K	Buy	+2,740	New	+$546K	﹤0.01%	2976

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Millennium Management's KPTI Position: Q1 2026 in Review

Millennium Management opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2026: 420,571 shares worth $2.34M. The stake represents ﹤0.01% of the portfolio and ranks #3729 among its holdings. This is a return to the name: Millennium Management previously reported a position in KPTI as recently as Q2 2025.

Millennium Management first reported a position in KPTI in Q4 2013 and has held it in 44 quarters since. The position peaked at $38.6M in Q4 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

Millennium Management held 420,571 shares of Karyopharm Therapeutics worth $2.34M as of Q1 2026.
Karyopharm Therapeutics was a new Millennium Management position in Q1 2026.
Karyopharm Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3729 holding.
Millennium Management first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 44 quarters since.
Millennium Management's Karyopharm Therapeutics position peaked at $38.6M in Q4 2020.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.